<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NASCOBAL- cyanocobalamin spray </strong><br>QOL Medical, LLC<br></p></div>
<h1>Nascobal®<br>Nasal spray<br>(Cyanocobalamin, USP)<br>500 mcg/spray<br>2.3 mL (8 sprays)</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="description"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"> Cyanocobalamin is a synthetic form of vitamin B<span class="Sub">12</span> with equivalent vitamin B<span class="Sub">12</span> activity. The chemical name is 5,6-dimethyl-benzimidazolyl cyanocobamide. The cobalt content is 4.35%. The molecular formula is C<span class="Sub">63</span>H<span class="Sub">88</span>CoN<span class="Sub">14</span>O<span class="Sub">14</span>P, which corresponds to a molecular weight of 1355.38 and the following structural formula:</p>
<p><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=EE2B4869-CD13-489B-B12F-1CE4FE081157&amp;name=nascobal_spray-chemstruct.jpg"><p class="MultiMediaCaptionNotCentered"></p></p>
<p>Cyanocobalamin occurs as dark red crystals or orthorhombic needles or crystalline red powder. It is very hygroscopic in the anhydrous form, and sparingly to moderately soluble in water (1:80). Its pharmacologic activity is destroyed by heavy metals (iron) and strong oxidizing or reducing agents (vitamin C), but not by autoclaving for short periods of time (15-20 minutes) at 121°C. The vitamin B<span class="Sub">12</span> coenzymes are very unstable in light.</p>
<p>Nascobal<span class="Sup">®</span> Nasal Spray is a solution of Cyanocobalamin, USP (vitamin B<span class="Sub">12</span>) for administration as a spray to the nasal mucosa. Each bottle of Nascobal Nasal Spray contains 2.3 mL of a 500 mcg / 0.1 mL solution of cyanocobalamin with sodium citrate, citric acid, glycerin and benzalkonium chloride in purified water. The spray solution has a pH between 4.5 and 5.5. The spray pump unit must be fully primed (see <span class="Bold"><a href="#dosageAdmin">DOSAGE AND ADMINISTRATION</a></span>) prior to initial use. After initial priming, each spray delivers an average of 500 mcg of cyanocobalamin and the 2.3 mL of spray solution contained in the bottle will deliver 8 doses of Nascobal Nasal Spray. The unit must be re-primed before each dose. (See <span class="Bold"><a href="#dosageAdmin">DOSAGE AND ADMINISTRATION</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="clinPharm"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY </h1>
<div class="Section" data-sectionCode="43679-0">
<a name="mechanismAction"></a><a name="section-3.1"></a><p></p>
<h2>GENERAL PHARMACOLOGY AND MECHANISM OF ACTION</h2>
<p class="First">Vitamin B<span class="Sub">12</span> is essential to growth, cell reproduction, hematopoiesis, and nucleoprotein and myelin synthesis. Cells characterized by rapid division (e.g., epithelial cells, bone marrow, myeloid cells) appear to have the greatest requirement for vitamin B<span class="Sub">12</span>. Vitamin B<span class="Sub">12</span> can be converted to coenzyme B<span class="Sub">12</span> in tissues, and as such is essential for conversion of methylmalonate to succinate and synthesis of methionine from homocysteine, a reaction which also requires folate. In the absence of coenzyme B<span class="Sub">12</span>, tetrahydrofolate cannot be regenerated from its inactive storage form, 5-methyltetrahydrofolate, and a functional <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folate deficiency</span> occurs. Vitamin B<span class="Sub">12</span> also may be involved in maintaining sulfhydryl (SH) groups in the reduced form required by many SH-activated enzyme systems. Through these reactions, vitamin B<span class="Sub">12</span> is associated with fat and carbohydrate metabolism and protein synthesis. Vitamin B<span class="Sub">12</span> deficiency results in <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span>, GI lesions, and neurologic damage that begins with an inability to produce myelin and is followed by gradual degeneration of the axon and nerve head.</p>
<p>Cyanocobalamin is the most stable and widely used form of vitamin B<span class="Sub">12</span>, and has hematopoietic activity apparently identical to that of the antianemia factor in purified liver extract. The information below, describing the clinical pharmacology of cyanocobalamin, has been derived from studies with injectable vitamin B<span class="Sub">12</span>.</p>
<p>Vitamin B<span class="Sub">12</span> is quantitatively and rapidly absorbed from intramuscular and subcutaneous sites of injection. It is bound to plasma proteins and stored in the liver. Vitamin B<span class="Sub">12</span> is excreted in the bile and undergoes some enterohepatic recycling. Absorbed vitamin B<span class="Sub">12</span> is transported via specific B<span class="Sub">12</span> binding proteins, transcobalamin I and II, to the various tissues. The liver is the main organ for vitamin B<span class="Sub">12</span> storage.</p>
<p>Parenteral (intramuscular) administration of vitamin B<span class="Sub">12</span> completely reverses the <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span> and GI symptoms of vitamin B<span class="Sub">12</span> deficiency; the degree of improvement in <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">neurologic symptoms</span> depends on the duration and severity of the lesions, although progression of the lesions is immediately arrested.</p>
<p>Gastrointestinal absorption of vitamin B<span class="Sub">12</span> depends on the presence of sufficient intrinsic factor and calcium ions. Intrinsic factor deficiency causes <span class="product-label-link" type="condition" conceptid="432295" conceptname="Pernicious anemia">pernicious anemia</span>, which may be associated with subacute combined degeneration of the spinal cord. Prompt parenteral administration of vitamin B<span class="Sub">12</span> prevents progression of neurologic damage.</p>
<p>The average diet supplies about 4 to 15 mcg/day of vitamin B<span class="Sub">12</span> in a protein-bound form that is available for absorption after normal digestion. Vitamin B<span class="Sub">12</span> is not present in foods of plant origin, but is abundant in foods of animal origin. In people with normal absorption, deficiencies have been reported only in strict vegetarians who consume no products of animal origin (including no milk products or eggs).</p>
<p>Vitamin B<span class="Sub">12</span> is bound to intrinsic factor during transit through the stomach; separation occurs in the terminal ileum in the presence of calcium, and vitamin B<span class="Sub">12</span> enters the mucosal cell for absorption. It is then transported by the transcobalamin binding proteins. A small amount (approximately 1% of the total amount ingested) is absorbed by simple diffusion, but this mechanism is adequate only with very large doses. Oral absorption is considered too undependable to rely on in patients with <span class="product-label-link" type="condition" conceptid="432295" conceptname="Pernicious anemia">pernicious anemia</span> or other conditions resulting in <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span> of vitamin B<span class="Sub">12</span>.</p>
<p>Colchicine, para-aminosalicylic acid, and heavy alcohol intake for longer than 2 weeks may produce <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span> of vitamin B<span class="Sub">12</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="pharmacokinetics"></a><a name="section-3.2"></a><p></p>
<h2>PHARMACOKINETICS</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="absorption"></a><a name="section-3.2.1"></a><p></p>
<h3>Absorption</h3>
<p class="First">A three way crossover study in 25 fasting healthy subjects was conducted to compare the bioavailability of the B<span class="Sub">12</span> nasal spray to the B<span class="Sub">12</span> nasal gel and to evaluate the relative bioavailability of the nasal formulations as compared to the intramuscular injection. The peak concentrations after administration of intranasal spray were reached in 1.25 +/- 1.9 hours. The average peak concentration of B<span class="Sub">12</span> obtained after baseline correction following administration of intranasal spray was 757.96 +/- 532.17 pg/mL. The bioavailability of the nasal spray relative to the intramuscular injection was found to be 6.1%. The bioavailability of the B<span class="Sub">12</span> nasal spray was found to be 10% less than the B<span class="Sub">12</span> nasal gel. The 90% confidence intervals for the log<span class="Sub">e</span>-transformed AUC<span class="Sub">(0-t)</span> and C<span class="Sub">max</span> was 71.71% - 114.19% and 71.6% - 118.66% respectively.</p>
<p>In <span class="product-label-link" type="condition" conceptid="432295" conceptname="Pernicious anemia">pernicious anemia</span> patients, once weekly intranasal dosing with 500 mcg B<span class="Sub">12</span> gel resulted in a consistent increase in pre-dose serum B<span class="Sub">12</span> levels during one month of treatment (p &lt; 0.003) above that seen one month after 100 mcg intramuscular dose (Figure).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="distribution"></a><a name="section-3.2.2"></a><p></p>
<h3>Distribution</h3>
<p class="First"> In the blood, B<span class="Sub">12</span> is bound to transcobalamin II, a specific B-globulin carrier protein, and is distributed and stored primarily in the liver and bone marrow.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="elimination"></a><a name="section-3.2.3"></a><p></p>
<h3>Elimination</h3>
<p class="First">About 3-8 mcg of B<span class="Sub">12</span> is secreted into the GI tract daily via the bile; in normal subjects with sufficient intrinsic factor, all but about 1 mcg is reabsorbed. When B<span class="Sub">12</span> is administered in doses which saturate the binding capacity of plasma proteins and the liver, the unbound B<span class="Sub">12</span> is rapidly eliminated in the urine. Retention of B<span class="Sub">12</span> in the body is dose-dependent. About 80-90% of an intramuscular dose up to 50 mcg is retained in the body; this percentage drops to 55% for a 100 mcg dose, and decreases to 15% when a 1000 mcg dose is given.</p>
<p><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=EE2B4869-CD13-489B-B12F-1CE4FE081157&amp;name=nascobal_spray-figure.JPG"><p class="MultiMediaCaptionNotCentered"></p></p>
<p>Figure. Vitamin B<span class="Sub">12</span> Serum Trough Levels After Intramuscular Solution (IM) of 100 mcg and Nasal Gel (IN) Administration of 500 mcg Cyanocobalamin After Weekly Doses.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="indicationsUsage"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE </h1>
<p class="First">Nascobal Nasal Spray is indicated for the maintenance of normal hematologic status in <span class="product-label-link" type="condition" conceptid="432295" conceptname="Pernicious anemia">pernicious anemia</span> patients who are in remission following intramuscular vitamin B<span class="Sub">12</span> therapy and who have no nervous system involvement.</p>
<p>Nascobal Nasal Spray is also indicated as a supplement for other vitamin B<span class="Sub">12</span> deficiencies, including: </p>
<p><span class="Bold">   I.</span>  Dietary deficiency of vitamin B<span class="Sub">12</span> occurring in strict vegetarians (Isolated vitamin B<span class="Sub">12</span> deficiency is very rare).</p>
<p><span class="Bold">   II.</span>  <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">Malabsorption</span> of vitamin B<span class="Sub">12</span> resulting from structural or functional damage to the stomach, where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates vitamin B<span class="Sub">12</span> absorption. These conditions include <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>, AIDS, Crohn's disease, tropical <span class="product-label-link" type="condition" conceptid="194992" conceptname="Celiac disease">sprue</span>, and <span class="product-label-link" type="condition" conceptid="194992" conceptname="Celiac disease">nontropical sprue</span> (idiopathic <span class="product-label-link" type="condition" conceptid="200146" conceptname="Pancreatic steatorrhea">steatorrhea</span>, gluten-induced enteropathy). <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">Folate deficiency</span> in these patients is usually more severe than vitamin B<span class="Sub">12</span> deficiency.</p>
<p><span class="Bold">   III.</span>  Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> (such as <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>, <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>, AIDS, certain <span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">endocrine disorders</span>, <span class="product-label-link" type="condition" conceptid="4146209" conceptname="Iron deficiency">iron deficiency</span>, and subtotal gastrectomy). Total gastrectomy always produces vitamin B<span class="Sub">12</span> deficiency. Structural lesions leading to vitamin B<span class="Sub">12</span> deficiency include regional <span class="product-label-link" type="condition" conceptid="4203614" conceptname="Ileitis">ileitis</span>, ileal resections, malignancies, etc.</p>
<p><span class="Bold">   IV.</span>  Competition for vitamin B<span class="Sub">12</span> by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B<span class="Sub">12</span> and infested patients often have associated gastric <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>. The blind loop syndrome may produce deficiency of vitamin B<span class="Sub">12</span> or folate. </p>
<p><span class="Bold">   V.</span>  Inadequate utilization of vitamin B<span class="Sub">12</span>. This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia.</p>
<p>It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span> (see <span class="Bold"><a href="#drugLabTestInteractions">Drug/Laboratory Test Interactions</a></span>), use of a gluten free diet in <span class="product-label-link" type="condition" conceptid="194992" conceptname="Celiac disease">nontropical sprue</span>, or administration of antibiotics in tropical <span class="product-label-link" type="condition" conceptid="194992" conceptname="Celiac disease">sprue</span>. Such measures remove the need for long-term administration of vitamin B<span class="Sub">12</span>.</p>
<p>Requirements of vitamin B<span class="Sub">12</span> in excess of normal (due to pregnancy, <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, malignancy, hepatic and <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>) can usually be met with intranasal or oral supplementation. </p>
<p>Nascobal Nasal Spray is not suitable for vitamin B<span class="Sub">12</span> absorption test (Schilling Test).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="contraindications"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATION</h1>
<p class="First">Sensitivity to cobalt and/or vitamin B<span class="Sub">12</span> or any component of the medication is a contraindication.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="warnings"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"> Patients with early Leber's disease (hereditary optic nerve <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>) who were treated with vitamin B<span class="Sub">12</span> suffered severe and swift <span class="product-label-link" type="condition" conceptid="372914" conceptname="Optic atrophy">optic atrophy</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> may occur in severe <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span> which is treated intensely with vitamin B<span class="Sub">12</span>. Folic acid is not a substitute for vitamin B<span class="Sub">12</span> although it may improve vitamin B<span class="Sub">12</span>-deficient <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span>. Exclusive use of folic acid in treating vitamin B<span class="Sub">12</span>-deficient <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span> could result in progressive and irreversible neurologic damage.</p>
<p><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic shock</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported after parenteral vitamin B<span class="Sub">12</span> administration. No such reactions have been reported in clinical trials with Nascobal Nasal Spray or Nascobal Nasal Gel.</p>
<p>Blunted or impeded therapeutic response to vitamin B<span class="Sub">12</span> may be due to such conditions as <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">uremia</span>, drugs having bone marrow suppressant properties such as chloramphenicol, and concurrent iron or <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folic acid deficiency</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="precautions"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="generalPrecautions"></a><a name="section-7.1"></a><p></p>
<h2>1. GENERAL</h2>
<p class="First">An intradermal test dose of parenteral vitamin B<span class="Sub">12</span> is recommended before Nascobal Nasal Spray is administered to patients suspected of cyanocobalamin sensitivity. Vitamin B<span class="Sub">12</span> deficiency that is allowed to progress for longer than three months may produce permanent degenerative lesions of the spinal cord. Doses of folic acid greater than 0.1 mg per day may result in hematologic remission in patients with vitamin B<span class="Sub">12</span> deficiency. Neurologic manifestations will not be prevented with folic acid, and if not treated with vitamin B<span class="Sub">12</span>, irreversible damage will result.</p>
<p>Doses of vitamin B<span class="Sub">12</span> exceeding 10 mcg daily may produce hematologic response in patients with <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folate deficiency</span>. Indiscriminate administration may mask the true diagnosis.</p>
<p>The validity of diagnostic vitamin B<span class="Sub">12</span> or folic acid blood assays could be compromised by medications, and this should be considered before relying on such tests for therapy.</p>
<p>Vitamin B<span class="Sub">12</span> is not a substitute for folic acid and since it might improve folic acid deficient <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span>, indiscriminate use of vitamin B<span class="Sub">12</span> could mask the true diagnosis.</p>
<p><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> and <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocytosis</span> could occur upon conversion of severe megaloblastic to normal erythropoiesis with vitamin B<span class="Sub">12</span> therapy. Therefore, serum potassium levels and the platelet count should be monitored carefully during therapy.</p>
<p>Vitamin B<span class="Sub">12</span> deficiency may suppress the signs of <span class="product-label-link" type="condition" conceptid="135214" conceptname="Polycythemia vera">polycythemia vera</span>. Treatment with vitamin B<span class="Sub">12</span> may unmask this condition.</p>
<p>If a patient is not properly maintained with Nascobal<span class="Sup">®</span> Nasal Spray, intramuscular vitamin B<span class="Sub">12</span> is necessary for adequate treatment of the patient. No single regimen fits all cases, and the status of the patient observed in follow-up is the final criterion for adequacy of therapy.</p>
<p>The effectiveness of Nascobal Nasal Spray in patients with <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> and <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infections</span> has not been determined. Therefore, treatment with Nascobal Nasal Spray should be deferred until symptoms have subsided.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="infoPatientPrecautions"></a><a name="section-7.2"></a><p></p>
<h2>2. INFORMATION FOR PATIENTS</h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="432295" conceptname="Pernicious anemia">pernicious anemia</span> should be instructed that they will require weekly intranasal administration of Nascobal Nasal Spray for the remainder of their lives. Failure to do so will result in return of the <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and in development of incapacitating and irreversible damage to the nerves of the spinal cord. Also, patients should be warned about the danger of taking folic acid in place of vitamin B<span class="Sub">12</span>, because the former may prevent <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> but allow progression of subacute combined degeneration of the spinal cord.</p>
<p>(Hot foods may cause nasal secretions and a resulting loss of medication; therefore, patients should be told to administer Nascobal Nasal Spray at least one hour before or one hour after ingestion of hot foods or liquids.)</p>
<p>A vegetarian diet which contains no animal products (including milk products or eggs) does not supply any vitamin B<span class="Sub">12</span>. Therefore, patients following such a diet should be advised to take Nascobal Nasal Spray weekly. The need for vitamin B<span class="Sub">12</span> is increased by pregnancy and lactation. Deficiency has been recognized in infants of vegetarian mothers who were breast fed, even though the mothers had no symptoms of deficiency at the time.</p>
<p>Because the nasal dosage forms of vitamin B<span class="Sub">12</span> have a lower absorption than intramuscular dosage, nasal dosage forms are administered weekly, rather than the monthly intramuscular dosage. As shown in the Figure above, at the end of a month, weekly nasal administration results in significantly higher serum vitamin B<span class="Sub">12</span> levels than after intramuscular administration. The patient should also understand the importance of returning for follow-up blood tests every 3 to 6 months to confirm adequacy of the therapy.</p>
<p>Careful instructions on the actuator assembly, removal of the safety clip, priming of the actuator and nasal administration of Nascobal Nasal Spray should be given to the patient. Although instructions for patients are supplied with individual bottles, procedures for use should be demonstrated to each patient.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="labTests"></a><a name="section-7.3"></a><p></p>
<h2>3. LABORATORY TESTS</h2>
<p class="First">Hematocrit, reticulocyte count, vitamin B<span class="Sub">12</span>, folate and iron levels should be obtained prior to treatment. If folate levels are low, folic acid should also be administered. All hematologic parameters should be normal when beginning treatment with Nascobal<span class="Sup">®</span> Nasal Spray.</p>
<p>Vitamin B<span class="Sub">12</span> blood levels and peripheral blood counts must be monitored initially at one month after the start of treatment with Nascobal<span class="Sup">®</span> Nasal Spray, and then at intervals of 3 to 6 months.</p>
<p>A decline in the serum levels of B<span class="Sub">12</span> after one month of treatment with B<span class="Sub">12</span> nasal spray may indicate that the dose may need to be adjusted upward. Patients should be seen one month after each dose adjustment; continued low levels of serum B<span class="Sub">12</span> may indicate that the patient is not a candidate for this mode of administration.</p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="432295" conceptname="Pernicious anemia">pernicious anemia</span> have about 3 times the incidence of carcinoma of the stomach as in the general population, so appropriate tests for this condition should be carried out when indicated.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="drugLabTestInteractions"></a><a name="section-7.4"></a><p></p>
<h2>4. DRUG/LABORATORY TEST INTERACTIONS</h2>
<p class="First">Persons taking most antibiotics, methotrexate or pyrimethamine invalidate folic acid and vitamin B<span class="Sub">12</span> diagnostic blood assays.</p>
<p>Colchicine, para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span> of vitamin B<span class="Sub">12</span>.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="carinMutaImpairFertility"></a><a name="section-7.5"></a><p></p>
<h2>5. CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY</h2>
<p class="First">Long-term studies in animals to evaluate carcinogenic potential have not been done. There is no evidence from long-term use in patients with <span class="product-label-link" type="condition" conceptid="432295" conceptname="Pernicious anemia">pernicious anemia</span> that vitamin B<span class="Sub">12</span> is carcinogenic. <span class="product-label-link" type="condition" conceptid="432295" conceptname="Pernicious anemia">Pernicious anemia</span> is associated with an increased incidence of carcinoma of the stomach, but this is believed to be related to the underlying pathology and not to treatment with vitamin B<span class="Sub">12</span>.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="pregnancy"></a><a name="section-7.6"></a><p></p>
<h2>6. PREGNANCY</h2>
<p class="First"> Pregnancy Category C: Animal reproduction studies have not been conducted with vitamin B<span class="Sub">12</span>. It is also not known whether vitamin B<span class="Sub">12</span> can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Adequate and well-controlled studies have not been done in pregnant women. However, vitamin B<span class="Sub">12</span> is an essential vitamin and requirements are increased during pregnancy. Amounts of vitamin B<span class="Sub">12</span> that are recommended by the Food and Nutrition Board, National Academy of Science - National Research Council for pregnant women should be consumed during pregnancy.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="nursingMothers"></a><a name="section-7.7"></a><p></p>
<h2>7. NURSING MOTHERS</h2>
<p class="First">Vitamin B<span class="Sub">12</span> appears in the milk of nursing mothers in concentrations which approximate the mother's vitamin B<span class="Sub">12</span> blood level. Amounts of vitamin B<span class="Sub">12</span> that are recommended by the Food and Nutrition Board, National Academy of Science-National Research Council for lactating women should be consumed during lactation.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="pediatricUse"></a><a name="section-7.8"></a><p></p>
<h2>8. PEDIATRIC USE</h2>
<p class="First">Intake in pediatric patients should be in the amount recommended by the Food and Nutrition Board, National Academy of Science-National Research Council.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ae"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The incidence of adverse experiences described in the Table below are based on data from a short-term clinical trial in vitamin B<span class="Sub">12</span> deficient patients in hematologic remission receiving Nascobal (Cyanocobalamin, USP) Gel for Intranasal Administration (N=24) and intramuscular vitamin B<span class="Sub">12</span> (N=25). In the pharmacokinetic study comparing Nascobal Nasal Spray and Nascobal Nasal Gel, the incidence of adverse events was similar.</p>
<p></p>
<a name="table2"></a><table frame="box" width="90%">
<caption><span>Table.  Adverse Experiences by Body System, Number of Patients and Number of Occurrences by Treatment Following Intramuscular and Intranasal Administration of Cyanocobalamin.</span></caption>
<colgroup>
<col width="25%">
<col width="30%">
<col align="center" width="17.5%">
<col align="center" width="17.5%">
</colgroup>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>There may be a possible relationship between these adverse experiences and the study drugs. These adverse experiences could have also been produced by the patient's clinical state or other concomitant therapy.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">Sore throat</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span></dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td align="center" rowspan="2" valign="middle"><p class="First"><span class="Bold">Body System</span></p></td>
<td align="center" rowspan="2" valign="middle"><p class="First"><span class="Bold">Adverse Experience</span></p></td>
<td align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Number of Patients (Occurrences)</span></p></td>
</tr>
<tr>
<td align="center" valign="top">
<p class="First"><span class="Bold">Vitamin B<span class="Sub">12</span> Nasal Gel, 500 mcg</span></p>
<p><span class="Bold">N=24</span></p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Intramuscular Vitamin B<span class="Sub">12</span>, 100 mcg</span></p>
<p><span class="Bold">N=25</span></p>
</td>
</tr>
<tr>
<td align="justify" rowspan="5" valign="top"><p class="First">Body as a Whole</p></td>
<td align="justify" valign="top"><p class="First">   <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td align="center" valign="top"><p class="First">1 (1)</p></td>
<td align="center" valign="top"><p class="First">4  (4)</p></td>
</tr>
<tr>
<td align="justify" valign="top"><p class="First">   <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></p></td>
<td align="center" valign="top"><p class="First">0 (0)</p></td>
<td align="center" valign="top"><p class="First">1  (1)</p></td>
</tr>
<tr>
<td align="justify" valign="top"><p class="First">   Generalized <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
<td align="center" valign="top"><p class="First">0 (0)</p></td>
<td align="center" valign="top"><p class="First">2  (3)</p></td>
</tr>
<tr>
<td align="justify" valign="top"><p class="First">   <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td align="center" valign="top"><p class="First">1 (2)<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td align="center" valign="top"><p class="First">5  (11)</p></td>
</tr>
<tr>
<td align="justify" valign="top"><p class="First">   <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></p></td>
<td align="center" valign="top"><p class="First">3 (4)</p></td>
<td align="center" valign="top"><p class="First">3  (3)</p></td>
</tr>
<tr>
<td align="justify" rowspan="1" valign="top"><p class="First">Cardiovascular System</p></td>
<td align="justify" valign="top"><p class="First">   <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">Peripheral Vascular Disorder</span></p></td>
<td align="center" valign="top"><p class="First">0 (0)</p></td>
<td align="center" valign="top"><p class="First">1  (1)</p></td>
</tr>
<tr>
<td align="justify" rowspan="5" valign="top"><p class="First">Digestive System</p></td>
<td align="justify" valign="top"><p class="First">   <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td align="center" valign="top"><p class="First">0 (0)</p></td>
<td align="center" valign="top"><p class="First">1  (2)</p></td>
</tr>
<tr>
<td align="justify" valign="top"><p class="First">   <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">Glossitis</span></p></td>
<td align="center" valign="top"><p class="First">1 (1)</p></td>
<td align="center" valign="top"><p class="First">0  (0)</p></td>
</tr>
<tr>
<td align="justify" valign="top"><p class="First">   <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td align="center" valign="top"><p class="First">1 (1)<a href="#footnote-1" class="Sup">*</a></p></td>
<td align="center" valign="top"><p class="First">1  (1)</p></td>
</tr>
<tr>
<td align="justify" valign="top"><p class="First">   <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> &amp; <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td align="center" valign="top"><p class="First">0 (0)</p></td>
<td align="center" valign="top"><p class="First">1  (1)</p></td>
</tr>
<tr>
<td align="justify" valign="top"><p class="First">   <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td align="center" valign="top"><p class="First">0 (0)</p></td>
<td align="center" valign="top"><p class="First">1  (1)</p></td>
</tr>
<tr>
<td align="justify" rowspan="2" valign="top"><p class="First">Musculoskeletal System</p></td>
<td align="justify" valign="top"><p class="First">   <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span></p></td>
<td align="center" valign="top"><p class="First">0 (0)</p></td>
<td align="center" valign="top"><p class="First">2  (2)</p></td>
</tr>
<tr>
<td align="justify" valign="top"><p class="First">   <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></p></td>
<td align="center" valign="top"><p class="First">0 (0)</p></td>
<td align="center" valign="top"><p class="First">1  (1)</p></td>
</tr>
<tr>
<td align="justify" rowspan="7" valign="top"><p class="First">Nervous System</p></td>
<td align="justify" valign="top"><p class="First">   <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">Abnormal Gait</span></p></td>
<td align="center" valign="top"><p class="First">0 (0)</p></td>
<td align="center" valign="top"><p class="First">1  (1)</p></td>
</tr>
<tr>
<td align="justify" valign="top"><p class="First">   <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></p></td>
<td align="center" valign="top"><p class="First">0 (0)</p></td>
<td align="center" valign="top"><p class="First">1  (1)<a href="#footnote-1" class="Sup">*</a></p></td>
</tr>
<tr>
<td align="justify" valign="top"><p class="First">   <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td align="center" valign="top"><p class="First">0 (0)</p></td>
<td align="center" valign="top"><p class="First">3  (3)</p></td>
</tr>
<tr>
<td align="justify" valign="top"><p class="First">   <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypoesthesia</span></p></td>
<td align="center" valign="top"><p class="First">0 (0)</p></td>
<td align="center" valign="top"><p class="First">1  (1)</p></td>
</tr>
<tr>
<td align="justify" valign="top"><p class="First">   <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">Incoordination</span></p></td>
<td align="center" valign="top"><p class="First">0 (0)</p></td>
<td align="center" valign="top"><p class="First">1  (2)<a href="#footnote-1" class="Sup">*</a></p></td>
</tr>
<tr>
<td align="justify" valign="top"><p class="First">   <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></p></td>
<td align="center" valign="top"><p class="First">0 (0)</p></td>
<td align="center" valign="top"><p class="First">1  (3)<a href="#footnote-1" class="Sup">*</a></p></td>
</tr>
<tr>
<td align="justify" valign="top"><p class="First">   <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></p></td>
<td align="center" valign="top"><p class="First">1 (1)</p></td>
<td align="center" valign="top"><p class="First">1  (1)</p></td>
</tr>
<tr>
<td align="justify" rowspan="2" valign="top"><p class="First">Respiratory System</p></td>
<td align="justify" valign="top"><p class="First">   <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td align="center" valign="top"><p class="First">0 (0)</p></td>
<td align="center" valign="top"><p class="First">1  (1)</p></td>
</tr>
<tr class="Last">
<td align="justify" valign="top"><p class="First">   <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></p></td>
<td align="center" valign="top"><p class="First">1 (1)<a href="#footnote-1" class="Sup">*</a></p></td>
<td align="center" valign="top"><p class="First">2  (2)</p></td>
</tr>
</tbody>
</table>
<p>
							The intensity of the reported adverse experiences following the administration of Nascobal (Cyanocobalamin, USP) Gel for Intranasal Administration and intramuscular vitamin B<span class="Sub">12</span> were generally mild. One patient reported severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> following intramuscular dosing. Similarly, a few adverse experiences of moderate intensity were reported following intramuscular dosing (two <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> and <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>; one <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>), and dosing with Nascobal (Cyanocobalamin, USP) Gel for Intranasal Administration (one <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>).</p>
<p>The majority of the reported adverse experiences following dosing with Nascobal (Cyanocobalamin, USP) Gel for Intranasal Administration and intramuscular vitamin B<span class="Sub">12</span> were judged to be intercurrent events. For the other reported adverse experiences, the relationship to study drug was judged as "possible" or "remote". Of the adverse experiences judged to be of "possible" relationship to the study drug, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>, and <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span> were reported following intramuscular vitamin B<span class="Sub">12</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> were reported following dosing with Nascobal (Cyanocobalamin, USP) Gel for Intranasal Administration.</p>
<p>The following adverse reactions have been reported with parenteral vitamin B<span class="Sub">12</span>:</p>
<p>Generalized:  <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic shock</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (see <span class="Bold"><a href="#warnings">WARNINGS</a></span> and <span class="Bold"><a href="#precautions">PRECAUTIONS</a></span>).</p>
<p>Cardiovascular:  <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Pulmonary edema</span> and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> early in treatment; peripheral vascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>.</p>
<p>Hematological:  <span class="product-label-link" type="condition" conceptid="135214" conceptname="Polycythemia vera">Polycythemia vera</span>.</p>
<p>Gastrointestinal:  Mild transient <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. </p>
<p>Dermatological:  <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">Itching</span>; transitory <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">exanthema</span>.</p>
<p>Miscellaneous:  Feeling of <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the entire body.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="overdosage"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">No overdosage has been reported with Nascobal Nasal Spray, Nascobal (Cyanocobalamin, USP) Gel for Intranasal Administration or parenteral vitamin B<span class="Sub">12</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="dosageAdmin"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended initial dose of Nascobal Nasal Spray is one spray (500 mcg) administered in ONE nostril once weekly. Nascobal Nasal Spray should be administered at least one hour before or one hour after ingestion of hot foods or liquids. Periodic monitoring of serum B<span class="Sub">12</span> levels should be obtained to establish adequacy of therapy.</p>
<p>Before the first dose and administration, the pump must be primed. Remove the clear plastic cover and the plastic safety clip from the pump. To prime the pump, place nozzle between the first and second finger with the thumb on the bottom of the bottle. Pump the unit firmly and quickly until the first appearance of spray. Then prime the pump an additional 2 times. Now the nasal spray is ready for use. The unit must be re-primed before each dose. Prime the pump <span class="Bold Underline">once</span> immediately before each administration of doses 2 through 8.</p>
<p><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=EE2B4869-CD13-489B-B12F-1CE4FE081157&amp;name=nascobal_spray-instruction1.jpg"><p class="MultiMediaCaptionNotCentered"></p></p>
<p>See <span class="Bold Underline"><a href="#labTests">LABORATORY TESTS</a></span> for monitoring B<span class="Sub">12</span> levels and adjustment of dosage.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="howSupplied"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Nascobal Nasal Spray is available as a spray in 3 mL glass bottles containing 2.3 mL of solution. It is available in a dosage strength of 500 mcg per actuation (0.1 mL/actuation). A screw-on actuator is provided. This actuator, following priming, will deliver 0.1 mL of the spray. Nascobal Nasal Spray is provided in a carton containing a nasal spray actuator with dust cover, a bottle of nasal spray solution, and a package insert. One bottle will deliver 8 doses (NDC 67871-773-35).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="pharmacistAssemblyInstructions"></a><a name="section-12"></a><p></p>
<h1>PHARMACIST ASSEMBLY INSTRUCTIONS FOR NASCOBAL NASAL SPRAY</h1>
<p class="First"> The pharmacist should assemble the Nascobal Nasal Spray unit prior to dispensing to the patient, according to the following instructions:</p>
<ol>
<li>Open the carton and remove the spray actuator and spray solution bottle.</li>
<li>Assemble Nascobal Nasal Spray by first unscrewing the white cap from the spray solution bottle and screwing the actuator unit tightly onto the bottle. Make sure the clear dust cover is on the pump unit.</li>
<li>Return the Nascobal Nasal Spray bottle to the carton for dispensing to the patient.</li>
</ol>
<p><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=EE2B4869-CD13-489B-B12F-1CE4FE081157&amp;name=nascobal_spray-instruction2.jpg"><p class="MultiMediaCaptionNotCentered"></p></p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="informationPatients"></a><a name="section-13"></a><p></p>
<h1>INFORMATION FOR PATIENTS</h1>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="432295" conceptname="Pernicious anemia">pernicious anemia</span> should be instructed that they will require weekly intranasal administration of Nascobal Nasal Spray for the remainder of their lives. Failure to do so will result in return of the <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and in development of incapacitating and irreversible damage to the nerves of the spinal cord. Also, patients should be warned about the danger of taking folic acid in place of vitamin B<span class="Sub">12</span>, because the former may prevent <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> but allow progression of subacute combined degeneration of the spinal cord.</p>
<p>(Hot foods may cause nasal secretions and a resulting loss of medication; therefore, patients should be told to administer Nascobal Nasal Spray at least one hour before or one hour after ingestion of hot foods or liquids.)</p>
<p>A vegetarian diet which contains no animal products (including milk products or eggs) does not supply any vitamin B<span class="Sub">12</span>. Therefore, patients following such a diet should be advised to take Nascobal Nasal Spray weekly. The need for vitamin B<span class="Sub">12</span> is increased by pregnancy and lactation. Deficiency has been recognized in infants of vegetarian mothers who were breast fed, even though the mothers had no symptoms of deficiency at the time.</p>
<p>Because the nasal dosage forms of Vitamin B<span class="Sub">12</span> have a lower absorption than intramuscular dosage, nasal dosage forms are administered weekly, rather than the monthly intramuscular dosage. As shown in the Figure above, at the end of a month, weekly nasal administration results in significantly higher serum Vitamin B<span class="Sub">12</span> levels than after intramuscular administration. The patient should also understand the importance of returning for follow-up blood tests every 3 to 6 months to confirm adequacy of the therapy.</p>
<p>Careful instructions on the actuator assembly, removal of safety clip, priming of the actuator and nasal administration of Nascobal Nasal Spray should be given to the patient. Although instructions for patients are supplied with individual bottles, procedures for use should be demonstrated to each patient.</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="storageHandling"></a><a name="section-14"></a><p></p>
<h1>STORAGE CONDITIONS</h1>
<p class="First">Protect from light. Keep covered in carton until ready to use. Store upright at controlled room temperature 15°C to 30°C (59°F to 86°F). Protect from freezing.</p>
<p><span class="Bold">Mfd. for QOL Medical, LLC</span></p>
<p>Kirland, WA 98033, USA</p>
<p>1.866.469.3773</p>
<p>www.nascobal.com</p>
<p>3078</p>
<p>Rev. 02/06-05/06</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NASCOBAL 		
					</strong><br><span class="contentTableReg">cyanocobalamin spray</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67871-773</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">NASAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>cyanocobalamin</strong> (cyanocobalamin) </td>
<td class="formItem"></td>
<td class="formItem">500 ug</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium citrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>citric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>glycerin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong> benzalkonium chloride</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67871-773-35</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">8  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>QOL Medical, LLC</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 9/2006<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>75178615-4CB2-1B90-FAE8-832236072318</div>
<div>Set id: EE2B4869-CD13-489B-B12F-1CE4FE081157</div>
<div>Version: 1</div>
<div>Effective Time: 20060915</div>
</div>
</div> <div class="DistributorName">QOL Medical, LLC</div></p>
</body></html>
